Dogs and their owners have many challenges
Improve Canine Health:
Improved Animal Welfare:
Reduce the Pet Owner Stress:
Convenient Product Spray Format
New Therapeutic Tool for Veterinarians
The SMN-023 drug candidate has been de-risked across a number of important drug development dimensions including safety, efficacy, manufacturing, cost and intellectual property protection.
The next step in development is a dose confirmation study to advance SMN-023 to pivotal development. The dose confirmation study is expected to commence in summer 2018.
Following a positive outcome from this study, Simini will advance SMN-023 to complete one pivotal efficacy and one pivotal safety study to support a New Animal Drug Application with the US Food and Drug Administration.
We love technology.
Technology is both science and art.
The science is achieving maximum effect while providing the most convenient delivery.
The art is developing optimal applications or combining effects to produce great solutions.
Our focus is the art of technology.
Translating cutting edge science from human health into new and effective pharmaceuticals for companion animals.
To exhaustively survey the latest scientific developments in human health for opportunities to advance breakthrough therapies that can change treatment paradigms in animal health.
Utilize a specialized team to evaluate each opportunity across multiple disciplines including: pharmacology, safety/toxicology, manufacturing, regulatory, intellectual property and marketing.
Work closely with in-licensing partners to create an arrangement of aligned interests that will be supportive for the development programs of our partners as well as animal health applications.
Interact collaboratively with regulatory agencies to insure development plans address the needs of patients, owners and veterinarians.